Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript
Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript
ARAY - Accuray Incorporated
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$2.00
DETAILS
HIGH:
$2.00
LOW:
$2.00
MEDIAN:
$2.00
CONSENSUS:
$2.00
UPSIDE:
611.74%
Stock News
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
MADISON, Wis., Aug. 19, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026, ended June 30, 2026.
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments
MADISON, Wis., Aug. 12, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increased customer value, and enhance overall enterprise performance as the company continues to advance the strategic priorities in its recently announced transformation plan focused on sustainable, profitable growth.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
MADISON, Wis., Aug. 5, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2026, ended June 30, 2026, during a conference call hosted by company management at 1:30 p.m.
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
MADISON, Wis., July 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced a plan incorporating several decisive actions that will drive a significant improvement in its financial position, a fundamental change in its business strategy, the rollout of differentiated technology, and continued transformation in how the company operates.
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer.
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform.
Accuray Incorporated (ARAY) Q3 2026 Earnings Call Transcript
Accuray Incorporated (ARAY) Q3 2026 Earnings Call Transcript
Accuray Reports Fiscal 2026 Third Quarter Financial Results
MADISON, Wis., May 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2026.
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m.
Accuray (ARAY) to Release Quarterly Earnings on Wednesday
Accuray (NASDAQ: ARAY - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $111.90 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earning overview page for
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026.
Short Interest in Accuray Incorporated (NASDAQ:ARAY) Expands By 20.6%
Accuray Incorporated (NASDAQ: ARAY - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 6,598,752 shares, a growth of 20.6% from the February 26th total of 5,471,116 shares. Approximately 5.8% of the shares of the company are sold
Accuray Q2 Earnings Call Highlights
Accuray (NASDAQ: ARAY) executives used the company's fiscal second-quarter earnings call to outline progress on a broad transformation program while acknowledging that tariff impacts and geopolitical instability-particularly in China-pressured results and prompted a reset of full-year guidance. Transformation plan targets profitability and operational discipline CEO Steve La Neve said the company is executing a "comprehensive strategic,
Accuray Incorporated (ARAY) Q2 2026 Earnings Call Transcript
Accuray Incorporated (ARAY) Q2 2026 Earnings Call Transcript
Accuray Reports Fiscal 2026 Second Quarter Financial Results
MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025.
Acuitas Investments LLC Raises Stake in Accuray Incorporated $ARAY
Acuitas Investments LLC increased its position in shares of Accuray Incorporated (NASDAQ: ARAY) by 67.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,392,126 shares of the medical equipment provider's stock after acquiring an additional 966,100 shares during the quarter.
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m.